This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Gail Maderis
President and CEO at Antiva Biosciences


Gail Maderis is President & CEO of Antiva Biosciences, a venture-backed biopharmaceutical company pioneering topical antiviral therapies against HPV. Previously, Ms. Maderis led BayBio, Northern California’s life science industry organization.  From 2003-2009, she served as President and CEO of Five Prime Therapeutics, a protein discovery company focused on immuno-oncology. Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). She currently serves on the boards of NovaBay Pharmaceuticals (NBY), Valitor, BIO Emerging Companies, and is a Trustee of the U.C. Berkeley Foundation. In 2018, Ms. Maderis was named one of the Most Admired CEOs by the SF Business Times. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.

Gail Maderis's Network

Agenda Sessions

  • Women’s health: Progress and innovation driving an increase in investor interest - Hilton Union Square


Speakers at this event